ASH 2023 | NVG-111, a ROR1 targeting bispecific TCE, in R/R CLL and MCL: a proof of concept Phase I study
Parag Jasani, FRCPath, MBBS, MRCP, Royal Free London NHS Foundation Trust, London, UK, discusses a proof of concept, Phase I, dose-escalation trial (NCT04763083), which investigated the use of NVG-111, a ROR1 targeting bispecific T-cell engager (TCE), for the treatment of patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). As durable responses were observed in patients when administered in combination with ibrutinib and as monotherapy, this study provided evidence for targeting ROR1 in these malignancies. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Abbvie, Astra Zeneca.
